Do hospitals that participate in COVID-19 research differ from non-trial hospitals? A cross-sectional study of US hospitals
Authors:
Open Access
- 7 August 2023
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-4
Abstract
Objectives: To compare hospitals that did and did not participate in clinical trials evaluating potential inpatient COVID-19 therapeutics. Methods: We conducted a cross-sectional study of hospitals participating in trials that were registered on clinicaltrials.gov between April and August 2020. Using the 2019 RAND Hospital Dataset and 2019 American Community Survey, we used logistic regression modeling to compare hospital-level traits including demographic features between trial and non-trial hospitals. Results: We included 488 hospitals that were participating in 298 interventional trials and 4232 non-participating hospitals. After controlling for demographic and other hospital traits, we found that teaching status (OR 2.11, 95% CI 1.52–2.95), higher patient acuity (OR 7.48, 4.39, 13.1), and location in the Northeast (OR 1.83, 95% CI 1.18, 2.85) and in wealthier counties (OR: 1.32, 95% CI 1.16–1.51) were associated with increased odds of trial participation, while being in counties with more White residents was associated with reduced odds (OR 0.98, 95% CI 0.98–0.99). Conclusions: Hospitals participating and not participating in COVID-19 inpatient treatment clinical trials differed in many ways, resulting in important implications for the generalizability of trial data.Keywords
Funding Information
- National Institutes of Health (P30AG021684, ULL1TR001881)
- Google (PhD fellowship)
- National Science Foundation (GRFP)
This publication has 7 references indexed in Scilit:
- The Landscape of COVID-19 Research in the United States: a Cross-sectional Study of Randomized Trials Registered on ClinicalTrials.GovJournal of General Internal Medicine, 2021
- Racial and Ethnic Disparities in Clinical Trial Recruitment in the U.S.American Journal of Preventive Medicine, 2021
- Inequities in the Geographic Accessibility of COVID-19 Biomedical Therapeutic Trials in the United StatesJournal of General Internal Medicine, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Racial Disproportionality in Covid Clinical TrialsNew England Journal of Medicine, 2020
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007